Estimation of creatinine clearance in morbidly obese patients.
about
Feasibility of therapy with hypomethylating agents in patients with renal insufficiencyEvaluation of dose requirements for prolonged bivalirudin administration in patients with renal insufficiency and suspected heparin-induced thrombocytopenia.Hematological toxicity of carboplatin for gynecological cancer according to body mass index.Low serum creatinine is associated with type 2 diabetes in morbidly obese women and men: a cross-sectional studyBroad-spectrum β-lactams in obese non-critically ill patients.Estimating creatinine clearance: a meta-analysis.Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance.General anesthesia type does not influence serum levels of neutrophil gelatinase-associated lipocalin during the perioperative period in video laparoscopic bariatric surgery.Use of a simplified nomogram to individualize digoxin dosing versus standard dosing practices in patients with heart failure.Functional range of creatinine clearance for renal drug dosing: a practical solution to the controversy of which weight to use in the Cockcroft-Gault equation.Potentially inappropriate prescribing of primarily renally cleared medications for older veterans affairs nursing home patientsSimplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patientsDesigning drug regimens for special intensive care unit populations.Fat-free weight prediction in morbidly obese females.Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patientsTherapeutic drug monitoring to adjust dosing in morbid obesity - a new use for an old methodology.Pediatric Obesity: Pharmacokinetic Alterations and Effects on Antimicrobial Dosing.Creatinine-based equations for the adjustment of drug dosage in an obese population.Population pharmacokinetics of oseltamivir and oseltamivir carboxylate in obese and non-obese volunteers.Cockcroft-Gault revisited: New de-liver-ance on recommendations for use in cirrhosisThe effects of obesity on drug pharmacokinetics in humans.Interpreting different measures of glomerular filtration rate in obesity and weight loss: pitfalls for the clinician.Altered vancomycin pharmacokinetics in obese and morbidly obese patients: what we have learned over the past 30 years.Dosing considerations for obese patients receiving cancer chemotherapeutic agents.Improving Medication Dosing in the Obese Patient.Risk factors for polyuria in a cross-section of community psychiatric lithium-treated patients.Association between renal function and chemotherapy-related toxicity in older adults with cancer.Adherence to the 2009 consensus guidelines for vancomycin dosing and monitoring practices: a cross-sectional survey of U.S. hospitals.Population Pharmacokinetics and Pharmacodynamics of Meropenem in Nonobese, Obese, and Morbidly Obese Patients.Comprehensive Guidance for Antibiotic Dosing in Obese Adults.Bariatric surgery is associated with renal function improvement.Monitoring Enoxaparin with Antifactor Xa Levels in Obese Patients.Population pharmacokinetic analysis of oseltamivir and oseltamivir carboxylate following intravenous and oral administration to patients with and without renal impairment.Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections.A Survey of Pharmacists in Academia on the Current Practice of Estimation of Kidney Function for Antimicrobial Dosing in Adults.Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients.Evaluation of renal drug dosing: prescribing information and clinical pharmacist approaches.Comparison of methods for determination of glomerular filtration rate in hypertensive subjects with normal serum creatinine.Levofloxacin dosing regimen in severely morbidly obese patients (BMI ≥40 kg/m(2)) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoring.Comparative evaluation of the Cockcroft-Gault Equation and the Modification of Diet in Renal Disease (MDRD) study equation for drug dosing: an opinion of the Nephrology Practice and Research Network of the American College of Clinical Pharmacy.
P2860
Q28283836-7CB39006-F1A2-4B3F-8400-39D74B1F19ECQ33399307-1E17FBDC-9839-4D85-B083-B151FF45C89AQ33432963-3C439322-A5D7-4D52-90DA-230C23C408A1Q33557884-F51B11C2-9F98-49E5-B4AA-84F38CF39A84Q33839225-5AE532E6-BF34-41FD-BBDE-4EF4E4AB72FCQ34020802-3F677754-CF69-4D93-AD5B-05517CCC8A04Q34075909-F977ED78-D26F-4F8B-95BE-F0DDFB801A13Q34457840-C8A3ABC7-9753-4E88-9B27-9719147FF8CEQ34490600-A78D4AF0-6312-400B-936E-CE4B705DF3F9Q34767683-D0CAF334-A913-428D-B953-83243047A255Q35007528-95A21130-50C1-4E0C-A3F4-CC9F42748638Q35191383-254C1A6F-CB17-4F48-9179-61AA33AED482Q35544079-E8FADCC3-206C-4157-B237-6C0BBE6DF94DQ35602586-38AC0643-D792-483B-AD7C-C82AB5334A78Q35941403-6C9723BF-4482-4A0C-B3AB-48C47981E268Q36111191-688DBC91-D0A7-4A8E-AC71-43502224982DQ36247129-1C4753B4-C376-40F0-8615-C135EF682DBEQ36802097-58D2B871-1824-4CA8-92A9-693026B81AB8Q36924693-DDFB73BA-B886-4D96-B2BF-3439C4F05BECQ37628518-FB994AC0-5BA8-4748-A92E-997F0729D948Q37854751-C4FB49C1-9C6E-4261-B979-2B8B8B836CB6Q37970042-FD4F1729-6560-4870-A11B-E8954F0DFD4EQ37989803-5FD43A26-E390-40C3-B4F0-FDB8C3F4787DQ38164666-C0003E76-A62C-4BAE-8F62-66320A76C809Q38947388-0D1DEAA9-7091-4E8D-BBB4-B87E20878030Q39152568-2F02133C-1791-442D-A761-451780A6206DQ39179989-F845D194-562B-4F96-8569-6B36FDA6D9ECQ39375881-79AE4C44-DED1-49CB-822E-A55760308DFAQ39484436-9515F1FA-56E9-4F6D-902D-CF239D566439Q40067964-A763EFC3-0FF4-463B-87BB-67E6D397B5B5Q40140288-8DEA45F1-8D01-42C7-BDD9-493F4BE2E377Q40284785-323429EC-D147-4168-AD52-7C199CE35038Q41143036-356BC0A8-4ED2-4004-8CBA-81D76EFD7C6BQ41508527-4EC3D1C0-F270-44B8-87D6-AE29317B0C99Q41527326-37B7C601-4517-4B07-B920-071E53BD606DQ42254710-0739680B-CC89-4E6E-B899-2FEB55E26F0FQ42961049-18583D3B-D075-4597-9092-CCB09E591D92Q43119908-C40E55CC-BA2B-4E27-86D3-F395BAFDA1DCQ44455948-F9E42C85-2EB1-4331-B4CE-0FDDE52AABDBQ45191658-5F58C0C3-6916-43ED-B9DB-FC665AEC879B
P2860
Estimation of creatinine clearance in morbidly obese patients.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Estimation of creatinine clearance in morbidly obese patients.
@en
Estimation of creatinine clearance in morbidly obese patients.
@nl
type
label
Estimation of creatinine clearance in morbidly obese patients.
@en
Estimation of creatinine clearance in morbidly obese patients.
@nl
prefLabel
Estimation of creatinine clearance in morbidly obese patients.
@en
Estimation of creatinine clearance in morbidly obese patients.
@nl
P2093
P356
P1476
Estimation of creatinine clearance in morbidly obese patients.
@en
P2093
Amy Barton Pai
Jasmina A Demirovic
Manjunath P Pai
P304
P356
10.2146/AJHP080200
P577
2009-04-01T00:00:00Z